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 2 
Abstract 24 
Treatment goals in acromegaly include symptom relief, tumour control and reversal of the 25 
excess morbidity and mortality associated with the disorder. Cardiovascular complications 26 
include concentric biventricular hypertrophy and cardiomyopathy, hypertension, valvular 27 
heart disease and arrhythmias, while metabolic disturbance (insulin resistance/diabetes 28 
mellitus, dyslipidaemia) further increases the risk of cardiovascular and cerebrovascular 29 
events. Sleep disordered breathing (in the form of sleep apnoea) is also common in patients 30 
with acromegaly and may exacerbate cardiovascular dysfunction, in addition to contributing 31 
to impaired quality of life. Accordingly, and in keeping with evidence that cardiorespiratory 32 
complications in acromegaly are not automatically reversed/ameliorated simply through the 33 
attainment of ‘safe’ growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels, 34 
recent guidelines have emphasised the need not only to achieve stringent biochemical control, 35 
but also to identify and independently treat these comorbidities. It is important therefore that 36 
patients with acromegaly are systematically screened at diagnosis, and periodically thereafter, 37 
for the common cardiovascular and respiratory manifestations, and that biochemical targets 38 
do not become the only treatment goal. 39 
40 
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Introduction 41 
Acromegaly is associated with an increased mortality rate [1,2], with a meta-analysis of 16 42 
studies revealing a weighted mean of the standardised mortality ratio (SMR) of 1.72 (95% 43 
confidence interval 1.62-1.83) [3]. Variance across studies has been attributed to several 44 
factors, including differing background population mortality rates and the weighting of 45 
historical versus contemporary cases (with modern treatments for acromegaly and its 46 
associated comorbidities more effectively mitigating the adverse sequelae of this condition) 47 
[4]. The increased risk of premature death has been attributed to cardiovascular and 48 
cerebrovascular events, respiratory complications and malignant neoplasms [3,5,6]. 49 
Restoration of serum growth hormone (GH) and insulin-like growth factor 1 (IGF-1) to 50 
‘normal’ or ‘safe’ levels remains a central goal of modern acromegaly management, although 51 
several studies have shown a continuing excess mortality when compared with the general 52 
population [3,5]. One important consideration when interpreting these data is the frequent 53 
reliance on a single GH and/or IGF-1 measurement at the end of the follow-up period which, 54 
however, may not reflect the degree of disease control throughout a treatment period [7]. 55 
These findings have prompted several workers to highlight the importance of identifying and 56 
independently treating cardiovascular and respiratory comorbidities in acromegaly [8,9,10]. In 57 
this article we review the spectrum of cardiovascular disorders that may be seen in 58 
acromegaly and draw attention to sleep disordered breathing as both an under-recognised, and 59 
often inadequately treated comorbidity, especially in patients who have achieved satisfactory 60 
biochemical control following primary therapy.     61 
 62 
Cardiovascular complications 63 
Cardiovascular abnormalities are common in acromegaly and may include a specific 64 
(‘acromegalic’) cardiomyopathy, hypertension, altered vascular function (with increased 65 
arterial stiffness and impaired endothelial relaxation), cardiac valvular dysfunction, 66 
arrhythmias and premature coronary and cerebrovascular disease [11]. Insulin 67 
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resistance/diabetes mellitus and dyslipidaemia are frequent accompaniments of GH excess 68 
and may exacerbate cardiovascular disease.   69 
 70 
Hypertension 71 
Hypertension affects at least one third (and possibly up to a half) of all patients with 72 
acromegaly, and is a key negative prognostic factor for mortality [1,12,13,14]. It is present 73 
from the earliest stages and is not necessarily influenced by disease duration [15], although it 74 
is more common in older subjects, as in the general population. An elevation in diastolic 75 
pressure is usually the first and predominant finding and may be heralded by changes in 76 
vascular dynamics [12]. Minimally invasive vascular studies have revealed an increase in 77 
arterial pulse wave velocity (a measure of arterial stiffness) and a reduction in flow-mediated 78 
dilatation (signifying impaired endothelial function) in newly diagnosed patients [9], which 79 
are believed to be mediated, at least in part, by direct effects of GH and IGF-1 on the vascular 80 
tree [16]. Insulin resistance and hyperinsulinism, which are common metabolic sequelae of 81 
acromegaly, may also contribute to endothelial dysfunction [17].  82 
 83 
In addition to the direct effects of GH and IGF-1 on the vasculature, several other 84 
pathophysiological mechanisms have been postulated to contribute to hypertension in 85 
acromegaly [18], including GH-mediated increased renal tubular sodium reabsorption [19], 86 
and inhibition of atrial natiuretic peptide by IGF-1 [20]. Where present, elevated insulin levels 87 
may also lead to increased sodium reabsorption with activation of the renin-angiotensin-88 
aldosterone system. Each of these mechanisms serves to increase circulating plasma volume 89 
and raise blood pressure. Cardiac hypertrophy can both induce and be exacerbated by 90 
hypertension, and sleep apnoea may also be contributory. Finally, secondary changes 91 
(remodelling) in the vasculature are commonly seen in response to longstanding/established 92 
hypertension. 93 
 94 
Cardiomyopathy and cardiac dysfunction 95 
 5 
Both GH and IGF-1, acting through their respective receptors, mediate direct effects on 96 
cardiac myocytes, e.g. increasing intracellular calcium content and sensitivity, and thereby 97 
altering myocardial contractility [21]. Over time, exposure to chronically raised GH and IGF-98 
1 levels may lead to extracellular collagen deposition, myofibrillary derangement, 99 
lymphomononuclear infiltration and ultimately necrosis, resulting in a progressive change in 100 
cardiac architecture [1,22,23]. These changes are independent of, but may be exacerbated by 101 
coexistent hypertension. Classically, three stages of intrinsic heart disease are recognised in 102 
acromegaly: (i) biventricular concentric hypertrophy (Fig. 1a) with increased myocardial 103 
contractility and systolic output, which is typically combined with an increased heart rate to 104 
give a hyperkinetic syndrome, (ii) more pronounced hypertrophy with diastolic filling defects 105 
at rest (Fig. 1b) and systolic dysfunction during exertion, and (iii) end stage cardiomyopathy 106 
with diastolic and systolic dysfunction at rest manifesting as overt heart failure [24,25,26]. In 107 
addition to hypertension, arrhythmias, metabolic dysfunction and ischaemic coronary disease 108 
may all conspire to further impair cardiac performance. Screening for these complications and 109 
for other common vascular risk factors (e.g. smoking, dyslipidaemia) should therefore be 110 
performed in all patients. 111 
 112 
Valve disease 113 
An excess of cardiac valve disease has been reported in acromegaly [27]. It has been 114 
suggested that GH exposure mediates an increase in expression of matrix metalloproteinases, 115 
leading to matrix dysregulation and a predisposition to annular fragility and leaflet disarray 116 
[28,29]. The mitral and/or aortic valves are most commonly affected, predisposing to 117 
ventricular hypertrophy, arrhythmia and heart failure. An increase in aortic root diameter may 118 
be another important contributory factor in valve dysfunction [30,31].  The prevalence of at 119 
least mild valve disease has been reported in as many as a fifth of patients with acromegaly 120 
[32], and has been shown to be dependent on disease duration, which suggests a potentially 121 
cumulative effect of GH exposure. 122 
 123 
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Arrhythmias 124 
Paroxysmal atrial fibrillation and supraventricular tachycardia, sick sinus syndrome, 125 
ventricular ectopic beats and ventricular tachycardia have all been linked with acromegaly, 126 
particularly during physical exertion. In one study, arrhythmias were observed in 48% of 127 
patients [33]. Myocardial hypertrophy and areas of fibrosis may be contributory, and 128 
conduction abnormalities have been reported in 41–56% of cases [34,35]. 129 
 130 
Carotid and coronary artery atherosclerotic disease 131 
As already noted, cerebrovascular and cardiac events are among the most commonly reported 132 
causes of death in acromegaly [3,5,6]. Their aetiology is likely to be multifactorial, with 133 
important contributions from each of the specific comorbidities highlighted in this article, 134 
acting in concert with other commonly-recognised cardiovascular risk factors such as age, sex 135 
and smoking status. Interestingly, specific assessments of carotid and coronary artery disease 136 
in patients with acromegaly have yielded mixed results. For example, Kartal et al. (2010) [36] 137 
and Brevetti et al. (2002) [37] both observed an increase in carotid intima-media thickness in 138 
active acromegaly, whereas others have reported no significant increase [38]. Early post-139 
mortem studies suggested an increase in coronary artery atherosclerosis [39,40]. More recent 140 
studies have sought to use a combination of CT-derived calcium scores and conventional risk 141 
scores (Framingham risk score, European Society of Cardiology risk score) to define risk for 142 
coronary artery atherosclerosis. Cannavo et al. (2006) [41] identified 41% of patients with 143 
acromegaly to be at risk of coronary atherosclerosis, with approximately half exhibiting 144 
increased calcification. However, other non-invasive studies have failed to confirm these 145 
findings, reporting low risk rates for coronary artery disease and no correlation with GH 146 
status [42,43]. A recent retrospective study of patients with acromegaly attending a tertiary 147 
clinic in Mexico identified 8% of their cohort with symptomatic coronary artery disease, 148 
defined as a history of angina or a documented myocardial infarction [10]. 149 
 150 
Metabolic risk factors 151 
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Insulin resistance, diabetes mellitus and dyslipidaemia are more prevalent in acromegaly and 152 
are independent risk factors for cardiovascular disease [1]. The insulin resistance is largely 153 
driven by GH hypersecretion, with impaired glucose tolerance or frank type 2 diabetes 154 
subsequently manifesting in 15-38% of patients [6].  The effect of elevated GH levels on lipid 155 
metabolism is more complex, and likely to be related in part to the insulin response to the 156 
counter-regulatory effects of GH.  Broadly, an atherogenic profile is recognised, with reduced 157 
HDL cholesterol levels and elevated triglycerides [10]. A more detailed review of the 158 
metabolic sequelae of acromegaly is provided in the review of Colao and colleagues [1].    159 
 160 
Response of cardiovascular complications to primary acromegaly therapy 161 
Surgery remains the primary treatment modality for the majority of patients with acromegaly, 162 
with adjunctive roles for somatostatin analogues (SSAs), dopamine agonists, the GH-receptor 163 
antagonist pegvisomant and radiotherapy where surgery is not curative or possible. A key 164 
goal of treatment is to reduce serum GH and IGF-1 to ‘safe’ levels. Historically, post-165 
treatment GH levels of <2.5 mcg/L were reported to correlate with a normal life expectancy 166 
[44]. However, in papers reporting SMRs for different levels of post-treatment GH and IGF-1, 167 
the lowest mortality ratios were found in patients with the lowest post-treatment GH and IGF-168 
1 levels [3,45,46]. The recently published Endocrine Society guidelines now propose 169 
biochemical targets of a serum IGF-1 within the age-and sex-matched reference range and a 170 
random growth hormone of <1.0 mcg/L [6]. For a significant proportion of patients 171 
multimodal therapy is required to achieve these targets.  172 
 173 
Several groups have reported improvements in different cardiovascular parameters in 174 
response to primary acromegaly treatment. For example, follow-up at six months post-175 
transphenoidal surgery in a cohort of newly diagnosed patients revealed a reduction in left 176 
ventricular mass and an increase in diastolic function [47].  Lower diastolic blood pressure 177 
has also been reported post-surgery [48]. Similarly, somatostatin analogue (SSA) therapy has 178 
been shown to have a beneficial effects on blood pressure [49,50,51], and to bring about 179 
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significant improvements in left ventricular mass, systolic and diastolic function, and exercise 180 
tolerance [51,52,53,54].  Rhythm disturbances may improve following commencement of 181 
SSA therapy [50,55,56], but asymptomatic bradycardia is a potential side-effect. Little is 182 
known about the numbers/proportion of patients who require invasive interventions (e.g. 183 
ablation and/or permanent pacemaker). Valvular heart disease was not found to be influenced 184 
by treatment with somatostatin analogues [57]. Fewer studies have assessed cardiovascular 185 
outcomes following treatment with pegvisomant, although a reduction in diastolic and systolic 186 
blood pressure and left ventricular mass have been shown, as have improvements in cardiac 187 
and vascular dynamics [58,59]. 188 
 189 
Although biochemical targets remain central to modern acromegaly management, making the 190 
attainment of stringent biochemical thresholds the sole objective is not without its risks, 191 
especially at the level of the individual patient. For example, in the study of Ayuk and 192 
colleagues, a history of pituitary radiotherapy was independently identified as a cause of 193 
increased mortality in acromegaly [46], and the endocrinologist and oncologist must therefore 194 
carefully weigh the benefits of further lowering GH and IGF-1 levels versus the increased risk 195 
of cerebrovascular disease when deciding whether to proceed to radiotherapy.  196 
 197 
Equally importantly, ongoing/new cardiovascular complications must not be overlooked in 198 
those who have reached biochemical treatment targets. In our own cohort of 30 newly-199 
diagnosed, treatment-naive patients, who were studied both at baseline and following six 200 
months of SSA therapy, attainment of even stringent biochemical targets did not necessarily 201 
equate to uniform improvements in cardiovascular markers of disease activity, and in some 202 
patients a deterioration in one or more parameters was observed even when ‘safe’ GH and 203 
IGF-1 levels were reached [9] (Fig. 2). In contrast, not all patients with persistent acromegaly 204 
(raised GH and IGF-1) or ‘discordant’ biochemical responses (most commonly GH within 205 
target, but IGF-1 raised) exhibited ongoing complications of their acromegaly [9]. We also 206 
observed some important gender differences (e.g. left ventricular mass index improved in men 207 
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but not in women). Therefore, for the most part cardiovascular changes following SSA 208 
therapy were independent of GH and IGF-1 levels and showed considerable inter-individual 209 
variation [9].  210 
 211 
In recognition of the importance of directly addressing those factors which contribute to the 212 
excess morbidity and mortality associated with acromegaly, the recently published guidelines 213 
of the American Endocrine Society recommend assessment for hypertension and 214 
cardiovascular disease at diagnosis, with longitudinal monitoring and rigorous management of 215 
individual complications [6].  Similarly, a consensus guideline for the diagnosis and treatment 216 
of acromegaly complications [8] advises blood pressure monitoring at baseline and at 217 
intervals of six months thereafter, with electrocardiography and echocardiography at baseline, 218 
and repeated annually thereafter. Suggested screening modalities are summarised in Table 1.  219 
 220 
Specific cardiovascular risk-modifying therapies in patients with acromegaly need not differ 221 
from those used for the general population (e.g. statins, antihypertensive agents), and lifestyle 222 
modification remains an important part of any management strategy.  223 
 224 
Sleep disordered breathing 225 
Sleep disorders are common in acromegaly, in particular obstructive sleep apnoea (OSA), 226 
which affects more than two thirds of patients [9,60,61].  227 
 228 
Sleep apnoea  229 
OSA has been proposed to account for up to 25% of the excess mortality seen in untreated 230 
acromegaly [1,44]. When associated with excessive daytime somnolence, the obstructive 231 
sleep apnoea syndrome is diagnosed, which has significant ramifications for both quality of 232 
life and safety, e.g. in relation to driving or operating machinery [62,63,64]. Furthermore, 233 
OSA is independently associated with hypertension and cardiovascular disease, and has been 234 
linked in some studies to the development of the metabolic syndrome (insulin resistance, type 235 
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2 diabetes, dyslipidaemia) and hypogonadism [65,66,67,68], thereby exacerbating a number 236 
of the primary complications of acromegaly. 237 
 238 
The development of OSA in acromegaly has been linked to craniofacial, pharyngeal, 239 
laryngeal and bronchial soft tissue thickening, which all predispose to airway restriction, with 240 
further contributions in some patients from facial skeletal abnormalities and neuromuscular 241 
defects of the pharyngeal muscles [61]. As with the general population, male gender, 242 
increasing age and co-existent obesity are significant risk factors [69,70], and 243 
hypothyroidism, if present, also predisposes to OSA [71]. A small subset of patients 244 
experience central apnoeas, thought to result from modulation of central respiratory centre 245 
function, combined with an increased ventilatory threshold for carbon dioxide [72]. 246 
 247 
Assessment of sleep status in acromegaly 248 
Screening for symptoms suggestive of excessive daytime somnolence in the general 249 
population is commonly based on a questionnaire, the Epworth Sleepiness Scale (ESS)  [73], 250 
with a score of 10 or greater triggering more rigorous assessment using either pulse oximetry, 251 
which yields an oxygen desaturation index (DI), or polysomnography to derive an apnoea-252 
hypopnoea index (AHI). The latter remains the gold-standard investigation, but is technically 253 
more demanding and often requires an overnight stay in a specialist sleep unit [74]. In our 254 
study of 30 patients with newly-diagnosed acromegaly we observed OSA in 79% of cases by 255 
AHI criteria [9].  However, although there was a modest correlation between DI and AHI (R2 256 
0.63, P<0.0001), DI tended to underestimate the severity of OSA, with AHI categorising 9 as 257 
having mild OSA, 4 as moderate and 9 as severe while,  in marked contrast, DI identified 16 258 
cases of mild OSA, 4 moderate and only 3 severe [9].  Based on these findings, and given the 259 
high prevalence of OSA in acromegaly, we recommend polysomnography as the preferred 260 
method for screening for sleep apnoea. 261 
 262 
Response of sleep apnoea to primary acromegaly therapy 263 
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Biochemical control of acromegaly does not reliably predict reversal of sleep apnoea, whether 264 
following surgery or somatostatin analogue therapy [60,72,75,76,77]. Although many patients 265 
will demonstrate an improvement in symptoms, 40% of those with controlled acromegaly 266 
continue to suffer with sleep apnoea [61,77,78].  In our study of 30 newly diagnosed patients, 267 
there was marked variation in the response of OSA to medical treatment of acromegaly: 268 
despite clear evidence of an improvement in biochemical control in 93% of patients, only 269 
61% demonstrated an improvement in OSA as measured by AHI, while 9% showed no 270 
change and 30% in fact manifested a significant deterioration [9] (Fig. 3). 271 
 272 
Given that a significant proportion of patients with OSA may fail to respond to primary 273 
therapy for acromegaly, detection and specific targeted treatment [e.g. with continuous 274 
positive airway pressure ventilation (CPAP)] should be considered in all patients [6,79]. This 275 
is especially pertinent given the implications regarding the legal right to drive, and potential 276 
impact of coexistent OSA on other acromegaly comorbidities, although evidence for the 277 
efficacy of primary treatment of OSA in ameliorating these conditions remains mixed [61,80]. 278 
 279 
Summary 280 
The last decade has witnessed numerous advances in the treatment of acromegaly such that it 281 
is now unusual to encounter a patient in whom multimodal therapy cannot restore GH and 282 
IGF-1 to target levels. However, the need to remain vigilant and to screen for, and 283 
independently treat the well-recognised cardiovascular and respiratory complications of 284 
acromegaly is as pertinent today as it has ever been. In so doing, the clinician can be 285 
confident that he/she is maximising the chance of reversing those comorbidities that 286 
contribute most to the excess morbidity and mortality associated with this disorder. 287 
288 
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Figure legends 628 
 629 
Fig. 1 Cardiac changes in a 65-year-old woman with newly diagnosed acromegaly. a Two-630 
dimensional (parasternal long axis) echocardiography demonstrating increased thickness of 631 
the interventricular septum [1.32 cm (RR 0.60–1.00)] and left ventricular posterior wall [1.67 632 
cm (RR 0.60–1.00)]. b Doppler studies reveal diminished peak systolic velocity and reversal 633 
of the E/A ratio [i.e. the ratio of early passive (E), to late active (A, atrial), ventricular filling 634 
velocities; in a healthy heart, the E velocity is greater than the A velocity, but this ratio is 635 
reversed in the presence of diastolic dysfunction with impaired ventricular filling].  636 
 637 
Fig. 2 Divergent cardiovascular responses in two patients with newly diagnosed acromegaly 638 
treated with primary depot somatostatin analogue therapy for 6 months.  a In Patient 1 (a 46-639 
year-old man) GH and IGF-1 were both restored to safe levels following treatment (mean GH 640 
0.76 mcg/L; IGF-1 1.02 ×ULN), and accompanied by normalisation of systolic and diastolic 641 
blood pressure, a reduction in arterial stiffness (as determined by aPWV) and improved 642 
endothelial function (as shown by an increase in FMD); left ventricular size (measured as 643 
LVMI) was normal at baseline and not significantly changed following treatment. b Patient 2 644 
(a 51-year-old woman) exhibited comparable biochemical control to patient 1 (mean GH 0.71 645 
mcg/L and IGF-1 0.60 ×ULN) post-SSA therapy but in contrast, despite improvements in 646 
arterial stiffness and endothelial function, systolic and diastolic blood pressure and LVMI 647 
showed an unanticipated deterioration. Key: aPWV, arterial pulse wave velocity; BP, blood 648 
pressure; FMD, flow-mediated dilatation; GH, growth hormone; IGF-1, insulin-like growth 649 
factor-1; LVMI, left ventricular mass index; SSA, somatostatin analogue therapy.  650 
 651 
Fig. 3 Sleep apnoea is a common finding in newly diagnosed acromegaly, but does not 652 
necessarily improve in response to primary treatment of acromegaly. a Mean GH (average of 653 
8-10 samples from a day profile), b IGF-1 (relative to the age and sex-matched reference 654 
range) and c AHI are shown for 27 individuals pre- (circles) and post- (arrowheads) six 655 
 26 
months of somatostatin analogue therapy. Green lines represent a decrease and red an increase 656 
in each parameter. Despite normalisation, or near-normalisation, to GH and IGF-1 target 657 
levels, patients 3, 8, 15, 16 and 24 manifest an actual worsening of sleep apnoea compared to 658 
baseline and several other patients have persistent, clinically relevant, sleep apnoea (data 659 
adapted from Annamalai et al. 2013 [7]). Key: AHI, apnoea-hypopnoea index; GH, growth 660 
hormone; IGF-1, insulin-like growth factor-1. 661 
662 
 27 
Table 1. Screening for cardiovascular and respiratory comorbidities in acromegaly. 663 
___________________________________________________________________________ 664 
Comorbidity    Preferred screening modality  665 
___________________________________________________________________________ 666 
Hypertension Clinic blood pressure readings +/- ambulatory or 667 
home blood pressure monitoring*   668 
Cardiomyopathy   Echocardiography      669 
Cardiac valve disease   Echocardiography     670 
Arrhythmias Resting 12-lead ECG +/-24 h ambulatory ECG or 671 
event recorder if symptomatic 672 
Hyperglycaemia   Fasting plasma glucose, HbA1c 673 
Dyslipidaemia    Fasting lipid profile 674 
Sleep apnoea    Polysomnography 675 
___________________________________________________________________________ 676 
 677 
Note: Screening for each comorbidity should be undertaken at the time of diagnosis of 678 
acromegaly and on an annual basis thereafter, although more frequent monitoring may be 679 
required if symptoms and/or findings on previous investigations dictate, and less frequent 680 
screening may be appropriate in patients with well-controlled disease and no clinical features 681 
of concern.  682 
 683 
*raised values require confirmation with either 24hr ambulatory monitoring or serial home 684 
measurements [for example NICE (2011) Hypertension (update): full 685 
guideline.http://www.nice.org.uk/guidance/cg127/]. 686 
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